June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
KLF4 Promotes Corneal Epithelial Cell Fate by Suppressing Epithelial-Mesenchymal Transition
Author Affiliations & Notes
  • Anil Tiwari
    Ophthalmology , University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Chelsea L. Loughner
    Ophthalmology , University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Sudha Swamynathan
    Ophthalmology , University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Shivalingappa K Swamynathan
    Ophthalmology , University of Pittsburgh, Pittsburgh, Pennsylvania, United States
    Cell biology and Fox Center for Vision Restoration, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Anil Tiwari, None; Chelsea Loughner, None; Sudha Swamynathan, None; Shivalingappa Swamynathan, None
  • Footnotes
    Support  R01EY026533 from NEI, NIH,P30 EY08098 Core grant from NEI, NIH,Unrestricted grants from ‘Research to Prevent Blindness’ and the ‘Eye and Ear Foundation of Pittsburgh’
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2619. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Anil Tiwari, Chelsea L. Loughner, Sudha Swamynathan, Shivalingappa K Swamynathan; KLF4 Promotes Corneal Epithelial Cell Fate by Suppressing Epithelial-Mesenchymal Transition. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2619.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Previously, we reported that corneal epithelial (CE)-specific ablation of Klf4 results in disrupted CE integrity and barrier function. Here we test the hypothesis that KLF4 promotes CE cell fate by suppressing epithelial-mesenchymal transition (EMT).

Methods : CE-specific Klf4 ablation was achieved by feeding ternary transgenic Klf4LoxP/LoxP/ Krt12rtTA/rtTA/ Tet-O-Cre (Klf4Δ/ΔCE) mice with doxycycline-chow for 15 days. The wild type (WT; ternary transgenic littermates fed with normal chow) and Klf4Δ/ΔCE corneal histology was examined by hematoxylin and eosin-stained sections. The WT and Klf4Δ/ΔCE CE wound healing rate was compared by CE debridement using Algerbrush. The CE phenotype was evaluated in unwounded WT and Klf4Δ/ΔCE corneas and those subjected to CE debridement, by quantifying the expression of Krt12, Ki67, cyclin-D1, β-catenin, E-cadherin, survivin, and paxillin. TGF-β1 was used to induce EMT in human corneal limbal epithelial (HCLE) cells, following which KLF4 and EMT markers were quantified by QPCR, immunoblots and immunofluorescent staining.

Results : Klf4Δ/ΔCE corneas displayed thicker CE with 6-7 cell layers compared with 4-5 in the WT, abnormal stratification, 8.8-fold increased number of proliferative Ki67+ cells, up-regulation of survivin, β-catenin, cyclin-D1 and paxillin, and downregulation of E-cadherin and Krt12, consistent with loss of CE phenotype and EMT. Above features of EMT were exaggerated in Klf4Δ/ΔCE corneas subjected to epithelial debridement. Klf4Δ/ΔCE CE migrated faster, filling 93% of the debrided area within 16 hours of wounding, compared with 61% in the WT. HCLE cells undergoing TGF-β1-induced EMT in vitro evidenced by decreased levels of DSG1, E-cadherin, and ZO-1 coupled with increased nuclear localization of β-catenin, also displayed significant down-regulation of KLF4 (70%), consistent with its role in suppressing EMT.

Conclusions : Increased proliferation, migration, repression of CE markers, and up-regulation of mesenchymal markers in Klf4Δ/ΔCE CE coupled with downregulation of KLF4 in HCLE cells undergoing TGF-β1-induced EMT reveal that KLF4 promotes CE cell fate by suppressing EMT.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×